58-54-8C=C(CC)C(=O)c1ccc(OCC(=O)O)c(Cl)c1ClAVOLMBLBETYQHX-UHFFFAOYSA-NEthacrynic acid is a white solid. (NTP, 1992)
58-54-8Crystals
White, or practically white, crystalline powder
less than 1 mg/mL at 75 °F (NTP, 1992)
Sparingly soluble in water, aq acids; soluble in chloroform
Very slightly soluble in water but soluble in most organic solvents such as alcohols, chloroform, and benzene
1.94e-02 g/L
Breast Feeding; Lactation; Antihypertensive Agents; Loop Diuretics
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Pharmaceuticals
252 °F (NTP, 1992)
118.5-120.5
121-122 °C
122.5 °C
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P317, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 41 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
SYMPTOMS: Symptoms associated with exposure to this chemical may include fluid and electrolyte imbalances, gout, gastrointestinal disturbances, depression of formed elements of the blood, skin rashes, paresthesias and hepatic dysfunction. It may also cause transient or permanent deafness in rare cases.
The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl ethacrynic acid, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.
JONES HC; INTRAUTERINE OTOTOXICITY CASE REPORT AND REVIEW OF LITERATURE; J NATL MED ASSOC 65: 201 (1973) INTRAUTERINE OTOTOXICITY & REVIEW OF LITERATURE, INCLUDING ETHACRYNIC ACID IS DISCUSSED.
C - Cardiovascular system
QC - Cardiovascular system
Ethacrynic acid is a monosulfonamyl loop or high ceiling diuretic. Ethacrynic acid acts on the ascending limb of the loop of Henle and on the proximal and distal tubules. Urinary output is usually dose dependent and related to the magnitude of fluid accumulation. Water and electrolyte excretion may be increased several times over that observed with thiazide diuretics, since ethacrynic acid inhibits reabsorption of a much greater proportion of filtered sodium than most other diuretic agents. Therefore, ethacrynic acid is effective in many patients who have significant degrees of renal insufficiency. Ethacrynic acid has little or no effect on glomerular filtration or on renal blood flow, except following pronounced reductions in plasma volume when associated with rapid diuresis.
Ethacrynic acid inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. Diuretics also lower blood pressure initially by reducing plasma and extracellular fluid volume; cardiac output also decreases, explaining its antihypertensive action. Eventually, cardiac output returns to normal with an accompanying decrease in peripheral resistance. Its mode of action does not involve carbonic anhydrase inhibition.
Optimal diuretic activity depends on at least 2 structural requirements: (1) methylene and adjacent ketone groups capable of reacting with sulfhydryl radicals of presumed receptor, and (2) substituents on aromatic nucleus.
In vitro, ethacrynic acid inhibits the active transport of chloride in the lumen of the ascending limb of the loop of Henle, thereby diminishing reabsorption of sodium and chloride at that site. Because this inhibition occurred with lower concns of ethacrynic acid in the presence of cysteine, it has been proposed that the ethacrynate-cysteine metabolite is the most active form of the drug. The drug increases potassium excretion in the distal renal tubule. Ethacrynic acid does not inhibit carbonic anhydrase, and it is not an aldosterone antagonist. Aldosterone secretion may incr during therapy with the drug and may contribute to the hypokalemia caused by ethacrynic acid.
読み込み中…
DTXSID3025257CHEMBL456CHEBI:4876Ethacrynic acid is a white solid. (NTP, 1992)
Solid
Solns at pH 7 at 25 °C stable for short periods of time. Stability decreased with an incr in pH, temp and time. /sodium salt/
This compound is stable under normal laboratory conditions.
3.5
3.1
3.5
pKa'= 3.50
UV max (water): 225 nm(E=15287); Soluble in water at 25 °C: up to 9%; Solutions at pH 7 @ 25 °C stable for short periods of time. Stability decreased with increase in pH, temperature, and time. /Ethacrynate sodium/
Soluble in water @ 25 °C to the extent of about 7%; solutions of the sodium salt are relatively stable at pH 7 at room temperature for short periods but as the pH or temperature increase solutions are less stable /Ethacrynate sodium/
化学的特性White Solid
RAHN KH; CLINICAL PHARMACOLOGY OF DIURETICS; CLIN EXP HYPERTENS (A) 5(2): 157 (1983) A REVIEW OF THE CLINICAL PHARMACOLOGY OF DIURETICS, INCLUDING PHARMACODYNAMIC DRUG INTERACTIONS WITH DIURETICS.
KOECHEL DA; ETHACRYNIC ACID AND RELATED DIURETICS: RELATIONSHIP OF STRUCTURE TO BENEFICIAL AND DETRIMENTAL ACTIONS; ANNU REV PHARMACOL TOXICOL 21: 265 (1981) A REVIEW WITH 186 REFERENCES ON THE BENEFICIAL & DETRIMENTAL EFFECTS OF PHENOXYACETIC ACID-TYPE DIURETICS SUCH AS ETHACRYNIC ACID.
ETHACRYNIC ACID may react vigorously with strong oxidizing agents. Can react exothermically with reducing agents (such as alkali metals and hydrides) to release gaseous hydrogen. May react exothermically with acids. Reacts exothermically with all bases both organic (for example, the amines) and inorganic.
EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.
Store at or below 24 °C (75 °F). Protect from freezing. /Ethacrynic acid oral soln/
Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Store in a well-closed container. /Ethacrynic acid tablets/
Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. /Ethacrynate sodium for injection/
Should a spill occur while you are handling this chemical, FIRST REMOVE ALL SOURCES OF IGNITION, then you should dampen the solid spill material with 60-70% ethanol and transfer the dampened material to a suitable container. Use absorbent paper dampened with 60-70% ethanol to pick up any remaining material. Seal the absorbent paper, and any of your clothes, which may be contaminated, in a vapor-tight plastic bag for eventual disposal. Solvent wash all contaminated surfaces with 60-70% ethanol followed by washing with a soap and water soln. Do not reenter the contaminated area until the Safety Officer (or other responsible person) has verified that the area has been properly cleaned.
SMALL SPILLS AND LEAKAGE: Should a spill occur while you are handling this chemical, FIRST REMOVE ALL SOURCES OF IGNITION, then you should dampen the solid spill material with 60-70% ethanol and transfer the dampened material to a suitable container. Use absorbent paper dampened with 60-70% ethanol to pick up any remaining material. Seal the absorbent paper, and any of your clothes, which may be contaminated, in a vapor-tight plastic bag for eventual disposal. Solvent wash all contaminated surfaces with 60-70% ethanol followed by washing with a soap and water solution. Do not reenter the contaminated area until the Safety Officer (or other responsible person) has verified that the area has been properly cleaned.
SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.
RECOMMENDED RESPIRATOR: Where the neat test chemical is weighed and diluted, wear a NIOSH-approved half face respirator equipped with an organic vapor/acid gas cartridge (specific for organic vapors, HCl, acid gas and SO2) with a dust/mist filter. (NTP, 1992)
The high-ceiling diuretics may interact adversely with other drugs. Ethacrynic acid and furosemide are significantly bound to plasma albumin and may compete for sites on the protein with drugs such as warfarin and clofibrate. ...One should be judicious in the use of any cephalosporin in conjunction with...ethacrynic acid.
The ototoxic interaction between aminoglycoside antibiotics (Streptomycin, Kanamycin, etc.) and loop-inhibiting diuretics, such as ethacrynic acid, has been well documented. This interaction causes extensive destruction of the hair cells of the cochlea. Viomycin, Capreomycin, and Polymyxin B, when given with ethacrynic acid , were found to produce cochlear hair cell damage that was similar to that produced by aminoglycoside antibiotics admin with ethacrynic acid.
Treatment of mice with Neomycin (100 mg/kg bw, IM) 60 min prior to ethacrynic acid led to a 3-5 fold higher accumulation of ethacrynic acid in cochlear structures. It is suggested that Neomycin breaks down hemolabyrinthine or tissue permeability barriers and allows increased penetration of the other drug into the inner ear.
The temporal bones of a patient who suffered sudden deafness and ataxia after admin of both furosemide and ethacrynic acid, were examined by light and electron microscopy. There was no loss of hair or supporting cells. Some hair cells, in both the vestibular neuroepithelium and the organ of corti, particularly in the basal turn, were more densely staining and more granular than normal. Membrane whorls also were common within mitochondria of such cells. The endoplasmic reticulum of some spiral ganglion cells was dilated. The major cytologic changes were found in the stria vascularis of the cochlea and dark cell areas of the vestibular system. There was marked dilatation of the intercellular fluid spaces, consistent with the biochemical observation that loop diuretics interfere first with enzyme systems responsible for fluid transport within the inner ear.
For more Interactions (Complete) data for ETHACRYNIC ACID (11 total), please visit the HSDB record page.
Since diuresis and natriuresis occur so rapidly using ethacrynic acid, reductions in blood volume lead to a decrease in mean arterial pressure. Reduced cardiac index and reflex tachycardia can also occur due to the sudden decrease in preload. Within one use, intravenous ethacrynic acid can precipitate immediate volume depletion that can potentially be life-threatening. Because of this, close monitoring of blood pressure is advisable during use.
Currently, there is no antidote described in the literature for the toxicity of ethacrynic acid. Toxicity usually occurs in elderly patients with diminished renal function leading to volume depletion and, in some cases, toxicity. When adverse side effects occur, rapid discontinuation of ethacrynic acid and supportive care can lead to the resolution of symptoms.
The following may be especially important in patient monitoring... : Blood pressure measurements (recommended at periodic intervals in patients being treated for hypertension; selected patients may be taught to monitor their blood pressure at home and report the results at regular physician visits); Blood urea nitrogen and Carbon dioxide (determinations recommeded at periodic intervals during therapy); Electrolyte concns (determinations recommended at periodic intervals, especially if patients are also taking cardiac glycosides or systemic steroids, or when severe hepatic cirrhosis is present); Glucose, serum and Hepatic function and Renal function and Uric acid, serum (determinations recommended at periodic intervals); Hearing exams (recommended at periodic intervals in patients receiving prolonged high-dose iv therapy); Weight measurements (recommended prior to initiation of therapy and at periodic intervals during therapy to monitor water loss). /Loop diuretics/
/HUMAN EXPOSURE STUDIES/ Vertigo, tinnitus with a sense of fullness in the ears, and temporary (lasting 1-24 hr) or permanent deafness have occurred following use of ethacrynic acid. These effects are most likely to occur after iv admin of ethacrynate sodium in patients with severe impairment of renal function or in patients receiving other ototoxic drugs. Headache, fatigue, apprehension, and mental confusion have also occurred in patients receiving ethacrynic acid.
/HUMAN EXPOSURE STUDIES/ Ototoxicity in mother and newborn treated with diuretic and kanamycin in 3rd trimester.
Drug Induced Liver Injury Rank (DILIrank 2.0)
Ethacrynic acid
Ambiguous-DILI-concern
5
Adverse reactions
DOI:10.1016/j.drudis.2016.02.015
/LABORATORY ANIMALS: Acute Exposure/ The following early changes occurred in pinna reflex and in inner ear morphology of guinea pigs treated iv with ethacrynic acid (80 mg/kg): Transient loss of pinna reflex occurred in wide frequency range (20 K-500 HZ) immediately after the treatment. Narrowing of deeper capillary network of the stria vascularis occurred soon after the treatment. The change was reversible. Outer hair cells underwent cytoplasmic swelling and marked depression of supravital reduction of nitro-BT. These changes were reversible.
/LABORATORY ANIMALS: Acute Exposure/ In 2.5 hr after iv admin of ethacrynic acid (60 mg/kg) to guinea pigs, potential of ductus cochlearis fell, cochlear marginal cells showed morpholgical changes, involving stria vascularis and Reissner's membrane.
/LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ Ethacrynic acid given orally to mice @ dose of 100 mg/kg/day for 21 days decr blood sugar levels and liver phosphorylase levels and incr liver glycogen levels.
/LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ A 79 wk study in rats at doses up to 45 times the human dose revealed no evidence of a tumorigenic effect.
For more Non-Human Toxicity Excerpts (Complete) data for ETHACRYNIC ACID (8 total), please visit the HSDB record page.
The kinetics of degradation of ethacrynic acid solutions at concentrations of 22.1-149.2 mmol/l and at 20-60 °C, followed a 2nd order reaction and were fitted to the arrhenius equation using the least squares regression analysis. Degradation of ethacrynic acid produced a dimer through a Diels-Alder type condensation.
Thiazide diuretic overdose should be treated by immidiate evacuation of the stomach followed by supportive symptomatic treatment and monitoring of serum electrolyte concn and renal function. /Thiazide diuretics/
SKIN CONTACT: IMMEDIATELY flood affected skin with water while removing and isolating all contaminated clothing. Gently wash all affected skin areas thoroughly with soap and water. If symptoms such as redness or irritation develop, IMMEDIATELY call a physician and be prepared to transport the victim to a hospital for treatment.
INHALATION: IMMEDIATELY leave the contaminated area; take deep breaths of fresh air. If symptoms (such as wheezing, coughing, shortness of breath, or burning in the mouth, throat, or chest) develop, call a physician and be prepared to transport the victim to a hospital. Provide proper respiratory protection to rescuers entering an unknown atmosphere. ...
EYE CONTACT: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline soln for 20-30 min while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hopital even if no symptoms (such as redness or irritation) develop.
INGESTION: DO NOT INDUCE VOMITING. If the victim is conscious and not convulsing, give 1 or 2 glasses of water to dilute the chemical and IMMEDIATELY call a hospital or poison control center. Be prepared to transport the victim to a hopital if advised by a physician. If the victim is convulsing or unconscious, do not give anything by mouth, ensure that the victim's airway is open and lay the victim on his/her side with the head lower than the body. DO NOT INDUCE VOMITING. IMMEDIATELY transport the victim to a hospital.
LD50 Mouse iv 175 mg/kg /Ethacrynate sodium/
LD50 Mouse oral 627 mg/kg
LD50 Rat oral 1 g/kg
LD50 Rat ip 43 mg/kg
The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl ethacrynic acid, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.
...IRREVERSIBLY COMBINES WITH 2 THIOL GROUPS OF GLYCERALDEHYDE 3-PHOSPHATE DEHYDROGENASE, THUS INACTIVATING THE ENZYME. HOWEVER, IT IS NOT POSSIBLE TO ATTRIBUTE DIURETIC ACTION TO THIS TYPE OF BIOCHEMICAL REACTION...
Hepatic.
After iv admin (5 or 50 mg/kg) of (14)C-ethacrynic acid to rats 60-70% was excreted into bile within 4 hr; <25% was ethacrynic acid, the remainder was biotransformation products. The 2 major metabolites in bile were identified; one was the glutathione adduct (ethacrynic acid-GSH) and the other was ethacrynic acid-mercapturate. Approx 40% of either dose was excreted as ethacrynic acid-GSH. Ethacrynic acid-mercapturate accounted for 18% of the low dose and 30% of the high dose excreted into bile. Dogs given a 5 mg/kg dose (iv) excreted 25, 11, and 9% of the dose as ethacrynic acid-mercapturate, ethacrynic acid-cysteine and ethacrynic acid-GSH, respectively.
Animal studies indicate that ethacrynic acid is metabolized to a cysteine conjugate (which may contribute to the pharmacologic effects of the drug) and to an unstable, unidentified compound.
M5DP350VZV
ETHACRYNIC ACID
Physiologic Effects [PE] - Increased Diuresis at Loop of Henle
Established Pharmacologic Class [EPC] - Loop Diuretic
Ethacrynic acid is a Loop Diuretic. The physiologic effect of ethacrynic acid is by means of Increased Diuresis at Loop of Henle.
ETHACRYNIC ACID
Agents that promote the excretion of urine through their effects on kidney function.
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
Onset of action is rapid, usually within 30 minutes after an oral dose of ethacrynic acid or within 5 minutes after an intravenous injection of ethacrynic acid.
Thirty-five % or less of ethacrynic acid was excreted in urine of rats and dogs, regardless of mode of admin and 50% or more appeared in feces, suggesting hepatic elimination of the drug.
Renal elimination (67%), biliary/fecal (33%), 20% unchanged. /From table/
Ethacrynic acid is rapidly absorbed from the GI tract. Following oral admin, the diuretic effect occurs within 30 min and reaches a peak in approx 2 hr. The duration of action following oral admin is usually 6-8 hr but may continue up to 12 hr. Following IV admin of ethacrynate sodium, diuresis usually occurs within 5 min, reached a max within 15-30 min, and persists for approx 2 hr. In animals, substantial quantities of ethacrynic acid accumulate only in the liver. The drug does not enter the CSF. It is not known whether ethacrynic acid crosses the placenta or is distributed into milk in humans. ... Approx 30-65% of an IV dose of ethacrynate sodium is secreted by the proximal renal tubules and is excreted in urine; approx 35-40% is excreted in bile, partially as the cysteine conjugate. In dogs, approx 30-40% of the drug excreted in urine is unchanged, 20-30% is the cysteine conjugate, and 33-40% is an unstable, unidentified compound. The rate of urinary excretion of ethacrynic acid increases as urinary pH increases and is decreased by probenecid.
MEDICATION (VET)
MEDICATION
Preparation: ... E. M. Schultz, J. M. Sprague, BE 612755 ... eidem, US 3255241 (1962, 1966 both to Merck & Co.).
2,3-Dichlorophenoxyacetic acid is subjected to a Friedel-Crafts reaction with butyryl chloride to form the 4-butyryl derivative. This undergoes a Mannich reaction with formaldehyde and dimethylamine, the product decomposing thermally to introduce the methyl group
Ethacrynic acid /Edecrin/ is available for oral use as 25 and 50 mg tablets. The sodium salt of ethacrynic acid is available for intravenous use.
ethacrynic acid oral solution; ethacrynic acid tablets USP: 25 mg, 50 mg; ethacrynate sodium for injection USP: 50 mg
説明Ethacrynic acid is a loop diuretic with anticancer activity., It inhibits the Na-K-2Cl (NKCC) cotransporter in duck erythrocytes (IC50 = 0.18 mM) and ATP-dependent chloride uptake in rat renal plasma membrane vesicles when used at a concentration of 0.3 mM., Ethacrynic acid also inhibits glutathione S-transferase P1-1 (GSTP1-1) and GSTA3-3 (IC50s = 4.9 and ~0.4 μM, respectively), and inhibits Wnt/β-catenin signaling in a cell-based reporter assay. It is cytotoxic to primary chronic lymphocytic leukemia cells (IC50 = 8.56 μM), as well as MCF-7, MDA-MB-231, and 4T1 cancer cells (IC50s = 45.53, 39.64, and 25.23 μM, respectively). Ethacrynic acid (250 μg per day) increases tumor growth reduction induced by the EGFR family inhibitors afatinib (Item Nos. 11492 | 21567) or neratinib in a 4T1 murine breast cancer model. Formulations containing ethacrynic acid have been used in the treatment of edema.
使用Ethacrynic acid is a powerful diuretic prescribed for edema associated with cardiac insufficiency, renal edema that does not respond to other diuretics, and edema of the brain and lungs.
一般的な説明White solid.
定義ChEBI: An aromatic ether that is phenoxyacetic acid in which the phenyl ring is substituted by chlorines at positions 2 and 3, and by a 2-methylidenebutanoyl group at position 4. It is a loop diuretic used to treat high blood pressure resulting from diseases such as congestive heart failure, liver failure, and kidney failure. It is also a glutathione S-transferase (EC 2.5.1.18) inhibitor.